


Claims.

1. A tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative having the general Formula I



Formula I

Wherein

X is CH₂, O or S;

R represents 1-3 substituents independently selected from H, (C₁₋₄)alkyl, (C₁₋₄)alkoxy and halogen;

R₁ is (C₅₋₈)cycloalkyl;

R₂ is H or (C₁₋₄)alkyl;

R₃, R_{3'}, R₄, R_{4'}, R₅, R_{5'} and R_{6'} are independently hydrogen or (C₁₋₄)alkyl, optionally substituted with (C₁₋₄)alkoxy, OH or halogen;

R₆ is hydrogen or (C₁₋₄)alkyl, optionally substituted with (C₁₋₄)alkoxy, OH or halogen; or

R₆ forms together with R₇ a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S;

R₇ forms together with R₆ a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S; or

R₇ is H, (C₁₋₄)alkyl or (C₃₋₅)cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C₁₋₄)alkoxy; or a pharmaceutically acceptable salt thereof.

2. The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R is H and R₁ is cyclopentyl or cyclohexyl.

3. The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1 or 2, wherein X is CH₂ or O.

4. The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of any one of claims 1-3, wherein R, R₂, R₃, R_{3'}, R_{4'}, R₅, R_{5'} and R_{6'} are H; R₄, R₆ and R₇ are independently

H or (C₁₋₄)alkyl; or R₆ forms together with R₇ a 5- or 6-membered saturated heterocyclic ring and R₄ is H or (C₁₋₄)alkyl

5. The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of any one of claims 1-4
5 for use in therapy.

6. A pharmaceutical composition comprising a tricyclic 1-[(indol-3-yl)carbonyl]-
piperazine derivative of any one of claims 1-4 together with a pharmaceutically
acceptable carrier therefor.

10

7. Use of a tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of Formula I as
defined in claim 1, in the preparation of a medicament for the treatment of pain.

15